INDEX

Note: Page numbers in italics indicate photos/figures; tables are noted with t.

AACE. See American Association of Clinical Endocrinologists
AAOS. See American Academy of Orthopedic Surgeons
Abatacept, 226t, 227
Abdominal compartment syndrome, 334–335
Abilify, route of administration and dose ranges, 234t
ABNs. See Advance beneficiary notices
Acarbose, 133
ACCP. See American College of Chest Physicians
Accreditation Council for Graduate Medical Education, Residency Review Committee, 83
ACE inhibitors, 52, 53, 350, 375, 419, 420, 421, 504
ACE-I/ARB agents, AKI with coexisting conditions and, 508
Acetaminophen, 522, 525, 528, 529t, 532
ACGME. See Accreditation Council for Graduate Medical Education
Acidosis, 193, 196, 336
ACP. See American College of Physicians
Acetremra, 226t
ACTH. See Adrenocorticotropin hormone
Activated partial thromboplastin time (aPTT), 174
Active cycle breathing techniques, 125
Acupuncture, PONV management and, 429t, 433
Acute chest syndrome, 171
Acute kidney injury, 185
cancer patients and, 273
contrast-induced, 333
dialysis after cardiac surgery, clinical score for predicting, 503
hip fracture patients and, 314
incidence and severity of, in critically ill patients, 501
intraoperative risk factors, 505–506
major causes and differential diagnosis of, 194–195, 194t
outcomes in, 510–511
perioperative, definition and incidence of, 499–501
perioperative morbidity and mortality with, 187
postoperative, 193–195
assessment of, 506
early diagnosis with novel biomarkers, 507
preoperative risk factors, 501–505
prevention and treatment, 507–510
cryoprotective therapy, 508–509
extracorporeal therapies, 509
hemodynamic agents and diuretics, 507–508
risk index for patients undergoing general surgery, 188t
symptoms and signs of, 193
Acute Kidney Injury Network, 499, 500t
Acute normovolemic hemodilution, 294
Acute renal failure, 185, 289–290
Acute tubular necrosis, 193
ADA. See American Diabetes Association
Adalimumab, 226, 226t
ADDRESS trial, 401
Adrenal insufficiency, 398, 456–457, 457t
Adrenocorticotropin hormone, 54
Advance beneficiary notices, 90
Advil, 223
AF. See Atrial fibrillation
African-American infants, sickle-cell disease and, 170
Age
    acute renal failure and, 187
    cancer patients and, 274
    perioperative stroke and, 202
    pulmonary complications and, 117
AIHA. See Autoimmune hemolytic anemia
AKI. See Acute kidney injury
AKIN. See Acute Kidney Injury Network
Alanine aminotransferase (ALT) levels, elevated, 149
Alcohol abuse, 240, 242–243
Alcohol withdrawal
    pharmacological management of, 242
    signs/symptoms of intoxication and, 241
Alcohol withdrawal syndrome (AWS), 240, 243
Aleve, 223
Allergies, history, 37
Aloxi, 428
Alpha-2 adrenergic agonists, 409
Alpha-agonists, 52
Alpha-glucosidase inhibitors, 133
Alprazolam, 232, 241
ALT, preoperative lab testing, recommendations for, 41
Alvimopan, 305
Alzheimer’s disease, 440
AMA, documentation guidelines, 87
AMA/Specialty Society RVS Update Committee, 86
American Academy of Family Physicians, VTE guidelines, 478
American Academy of Orthopedic Surgeons, 316
American Association of Clinical Endocrinologists, 53, 136, 379
American Association of Orthopedic Surgery, 468
American Cancer Society, 267
American College of Cardiology/American Heart Association
    aspirin guidelines, 50
    CABG guidelines, 289
    cardiac testing guidelines, 255
carotid endarterectomy guidelines, 293
ECG recommendations, 42, 43
Echocardiography guidelines, 277
Focused Update on Perioperative Beta-Blockers, 108
guidelines for perioperative cardiac assessment, 313
heart failure guidelines, 421
ophthalmic surgeries and guidelines of, 374–375
Perioperative Cardiovascular Evaluation and Care guidelines, 408
perioperative guidelines and revisions, 37, 99, 104–105, 111, 302
simplified algorithm for perioperative cardiac risk assessment/care, 104, 105, 105
spine surgery and guidelines of, 340
American College of Chest Physicians, 210, 316, 387, 481
abdominal cancer surgery guidelines, 277–278
anticoagulation guidelines in postoperative AF, 418
ophthalmic surgeries and guidelines of, 376–377
thromboprophylaxis recommendations based on risk, 467
VTE guidelines, 465, 478
prophylaxis recommendations, 2008, 469–470
American College of Physicians
    patient- and procedure-related risk factors from, 116
pulmonary guidelines, 44, 115, 116, 117, 120
VTE guidelines, 478
American College of Surgeons, Advanced Trauma Life Support guidelines, 325–326
American Diabetes Association, 53, 136, 379
American Medical Association, CPT codes, 85, 86
American Medical Society, 86
American Psychiatric Association, 245
American Society of Anesthesiologists, 236, 291
classification scheme, 117
physical status classification system, 101, 102
American Society of Anesthesiology, physical status index, 487
American Society of Clinical Oncology, 277
VTE prophylaxis guidelines, 305
American Society of Regional Anesthesia, paraspinal hematoma recommendations, 180–181
American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guideline, 471, 472
American Surgical Association, craniotomy guidelines, 340
Aminocaproic acid, 294
Amiodarone, 52, 289
Ampicillin, 263
Anakinra, 226t, 227
Analgesia. See also Pain
patient-controlled, 527–532
regional techniques, 525–527
Anastomotic leaks, bariatric surgery and, 357, 358
Anemia, 163–173
autoimmune hemolytic anemia, 172–173
bleeding diathesis and, 197
cardiothoracic surgery and, preoperative through postoperative period, 293–294
diagnostic testing, 165–167
epidemiology, 163–164
history and physical examination, 164–165
IDA, 167–168
inflammatory bowel disease and, 302
iron-deficiency, 164
macrocytic, 166
microcytic, 166
normocytic, 166
orthopedic surgery patient and, 320
preoperative evaluation, 167
preoperative risk assessment, 164
sickle-cell disease, 170–172
thalassemia, 172
in trauma patients, 333
vitamin B12 and folate-deficiency anemia, 168
WHO definition, 163
Anemia of chronic disease
causes and hallmark of, 169–170
laboratory testing to differentiate IDA from, 170t
Anesthesia
Duchenne muscular dystrophy and, 210
pregnant patients and, 260
Anesthesia-run clinics, 64
Anesthesiology, medical consultation program and, 81
Anesthetic agents
chronic kidney disease and, 191
liver disease and, 155
Anesthetic history, 37
Aneurysms, cerebral, 207
CTA of subarachnoid hemorrhage in setting of, 348
Angiotensin receptor blockers, 52, 53, 375, 504
Angiotensin II receptor blockers, 421, 420
Ankylosing spondylitis (AS)
epidemiology, 218
examination, 219
history, 218–219
laboratory testing, 219
Antiarrhythmic drugs, 52
Antibiotic therapy, Surviving Sepsis Guidelines for, 393t
Anticholinergic agents, 430
Anticoagulant therapy
American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guideline, 471, 472t
perioperative pain control and, 527
Anticoagulants
new, 468
VTE treatment with, 478
Anticoagulation
management, 57–61
in neurosurgical setting, 351
Anticonvulsants, 236, 242
Antidepressants, 231, 235
Antidiuretic hormone, 343
Antiemetic medications/techniques
nonpharmacological prophylactic, 433
prophylactic, 427–432
Antiplatelet agents, 48–50, 61
Antipsychotic medications
classes of, 238
dementia patients and, FDA Black Box warning, 445
Anti-tumor necrosis factor (TNF) agents, 226
Anxiety disorder, 231–233
   behavior management, 233
   general considerations, 231–232
   medication management, 232–233
   preoperative treatment, 521–522
Anzemet, 428
AOCD. See Anemia of chronic disease
Aortic surgery, reducing PPC rates after, 125
Aortic valve replacement, 285
APA. See American Psychiatric Association
APACHE score, for acute illness, 441
API. See Apnea-Hypopnea Index
Apixaban, 468
Apnea-Hypopnea Index, 117
Appendectomy, 251
Aprepitant, 432
Aprotinin, 294
ARF. See Acute renal failure
Argatroban, 295
Arginine vasopressin, 343
Aripiprazole, 234, 237, 239
ARISE, 395
Arozullah Respiratory Failure Index, original, 122
Arrhythmias. See Cardiac arrhythmias
Arterial venous malformations, 207
Arthroplasty
   of hip and knee, 313
   preoperative assessment, 314
   VTE prophylaxis and, 316
Arthrotec, 223
ASA. See American Society of Anesthesiologists
ASCO. See American Society of Clinical Oncology
Ashkenazi Jews, factor XI deficiency among, 177
Aspart, 133
Aspirin, 36, 48, 49, 50, 223, 468
   low-dose, pregnancy and, 256
   surgeries, risk for hemorrhage and, 204
ASRA. See American Society of Regional Anesthesia
AST, preoperative lab testing, recommendations for, 41
Asthma, 117, 301
Atelectasis, 115, 291
Ativan, 232
ATN. See Acute tubular necrosis
Atorvastatin, 108, 109
Atrial arrhythmias, advanced age and, 416
Atrial fibrillation, 288–289, 413, 415
   ACC guidelines, Class I, IIa, and III, 418
   incidence, 288
   morbidity and mortality, 289
   prophylaxis and treatment, 289
   risk stratification, 289
Atrial flutter, 413, 415
Atrial natriuretic peptide, 507–508
Atypical antipsychotics, 237, 238
AUDIT questionnaire, 331
Autoimmune hemolytic anemia, 172–173
AVMs. See Arterial venous malformations
AVR. See Aortic valve replacement
Azathioprine, 226, 302
BARI. See Bypass Angioplasty Revascularization Investigation
BARI 2-D study, 106
Bariatric surgery
   obstructive sleep apnea and, 117–118
   VTE risk and, 303
Bariatric surgery patient, 357–370
   background on procedures for, 357
   discharge recommendations, 369
   physical examination
      cardiac evaluation, 361–362
      diabetes mellitus, 365–366
      HTN, 360
      pulmonary evaluation, 362, 364
   postoperative assessment/management
      cardiac, 366–367
      diabetes, 367–369
      HTN, 366
      pulmonary, 367
   preoperative assessment, 358–362, 364–366
      thrombotic risk assessment, 364, 366
      recommended nutritional supplementation for, 370
   surgery-specific risk to, 357–358
Barthel Index, for functional impairment, 441
Basal-bolus insulin, 133, 139, 144
Bayes’ theorem, 473
Benign prostatic hyperplasia, 194
Benzamides, PONV management and, 430, 431
Benzodiazepine equivalency, 232
Benzodiazepines, 57, 155, 231, 232–233, 235, 331, 347
   alcohol withdrawal and, 242–243
delirium and, 448
dialysis patients and, 191
benztropine, 238
beta-adrenergic antagonists, 50, 146
beta-blockers, 347, 350, 414, 419, 420, 421
ACC/AHA Guidelines, 408–409
cardiac events in patients undergoingvascular surgery and, 107
perioperative, 106–108, 110
perioperative stroke and, 206
betal-selective agents, 52
bevacizumab
cardiotoxicity and, 270
ischemia and, 271
bilirubin test, direct and indirect, 165
billing
   future issues with, 92
   perioperative medicine and, 89–90, 92
biologic agents, 226–227, 226
biomarkers
defined, 109
postoperative, 109–110
postoperative AKI and, 507
bipolar affective disorder, 233, 236–237
bipolar depression, 233
bisoprolol, 106, 107, 419
bispectral Index, 444
bivalirudin, 295
bleeding risk assessment, preoperativeevaluation, 173
bleomycin, pulmotoxicity and, 272, 272
blood conservation, perioperative,
multifaceted approach to, 167, 168
blood disorders, perioperative, 163–181
   anemia, 163–173
   bleeding disorders, 173–176
   hemophilia, 176–181
blood glucose levels, 136
blood transfusions, 294
   refusals due to religious reasons, 164
   sickle-cell disease, 171
blunt cardiac injury, 330–331
BNP. See B-type natriuretic peptide
body systems, for review of systems, 87–88
bone disease, metastatic, 313, 315
bone mineral density testing, 319
bone tumors, metastatic, 309–310
bowel perforation, 304
bowel resection surgeries, postoperativeileus and, 304, 305
BPH. See benign prostatic hyperplasia
bradyarrhythmias, 414
bradycardias, 414, 417
brain injury
dysautonomia and agitation related to,346, 347
traumatic, 326–328
brain trauma foundation, 327
breakeven point, 69
bridging therapy, thromboembolic risk and,59
Brigham and Women’s Hospital (Boston),
ECG retrospective study, 42
bromocriptine, 347
b-type natriuretic peptide, 42
Budd-Chiari syndrome, 157
bumetanide, 192
bUN, preoperative lab testing,
   recommendations for, 41
bundle branch blocks, 41
bundled payments, for hospitals andphysicians, rationale for, 92
bupivicaine, 526
buprenorphine, 243, 520, 521, 525
bupropion, 235
business case development, for UPAC,68–69
busulfan, pulmotoxicity and, 272
butyrophenones, PONV management and,430, 431
bypass angioplasty revascularization
   investigation, 293
BZDs, withdrawal signs/symptoms, 241
CABG. See coronary artery bypass grafting
cAD. See coronary artery disease
cage questionnaire, 240, 240, 331
calcium, 196, 319, 321
calcium channel blockers, 52
cancer patients, 267–279
   age of, 274
   cancer history, 269
   cardiovascular conditions in, 269, 270,271–272
diabetes in, 272–273
   epidemiology, 267–268
   history, 268–269
Cancer patients (cont’d)
nutrition status of, 274
patient education, 278–279
perioperative testing, 276–277
physical examination
  cardiovascular surgery, 275
  extremities, 276
gastrointestinal system, 275
head and neck, 275
neurologic system, 276
psychological system, 276
skin, 276
thorax, 275
postoperative management of, 268,
  277–278
pulmonary conditions, 272
quality indicators, 278
reasons for surgery, 268t
renal conditions in, 273–274
type of surgery, 274–275
*Candida* sp., surgical site infections, 487,
  488t
Carbamazepine, 236, 242
Carboplatin, renal side effects of, 273t
CARD2 quality metric, 110
Cardiac arrhythmias, 288, 412–418
  background, 412–414
  medical management, 417–418
  pathophysiology, 414
  postoperative assessment, 416–417
  prevention strategies, 414–416
  bradycardias and heart block, 414–415
  supraventricular arrhythmias, 415–416
  ventricular arrhythmias, 415
Cardiac catheterization, 362, 363t
Cardiac complications, postoperative,
  485–421
  arrhythmias, 412–418
  congestive heart failure, 418–421
  myocardial ischemia/myocardial
  infarction, 407–412
Cardiac conditions, that warrant evaluation/
treatment before noncardiac surgery, 102t
Cardiac evaluation, bariatric surgery
  patients, 361–362
Cardiac events, perioperative
  ameliorating, 97
  causes of, 97
Cardiac monitoring, post-bariatric surgery,
  366–367
Cardiac murmurs, 100
Cardiac outcomes
  postoperative biomarkers, 109–110
  postoperative EKG monitoring for
  ST-segment changes, 109
Cardiac risk factors, perioperative
  lowering, interventions for, 105–109
  beta-blockers, 106–108
  revascularization, 106
  statins, 108–109
  patient education, 110
Cardiac risk factors, preoperative, past
  medical history, 36
Cardiac surgery, 285–296
  atrial fibrillation, 288–289
  clinical score to predict AKI requiring
dialysis after, 503
  complications, 287–288
  diabetes, 293
  GI complications after cardiothoracic
  surgery, 295–296
  heart rate and rhythm, 288
  hematological complications, 293–295
  laboratory evaluation, 286
  neurologic complications and carotid
  artery disease, 292–293
  postoperative assessment and
  management, 287
  preoperative assessment, 286
  preoperative estimation of morbidity and
  mortality risk, 287
  pulmonary disease and, 291–292
  renal disease and, 289–291
  surgery specific risk, 285–286
Cardiac testing, 99
  comparison of modalities, 363t
  pregnancy and, 255–256
Cardiomyopathy, cancer patients and, 269,
  271
Cardiopulmonary exercise testing, 120
Cardiotoxicity, chemotherapeutic agents
  associated with, 270t
Cardiovascular complications, with
  abdominal and pelvic surgeries, 301
Cardiovascular conditions, cancer patients
  with, 269, 271–272
Cardiovascular disease, preoperative ECGs
  for patients with, 42
Cardiovascular evaluation, chronic kidney disease and, 189–191
Cardiovascular medications, 50, 52–53, 61
Cardiovascular physiology, pregnancy and, 252
Cardiovascular risk, perioperative, predicting, 101, 103–104
Cardiovascular surgery
  incidence of AKI after, 500
  outcomes in AKI after, 510–511
  peroperative and intraoperative risk factors of AKI after, 502–504, 502r
Carmustine, pulmotoxicity and, 272r
Carotid artery disease, 292–293
Carotid endarterectomy (CEA), 293
CARS. See Compensatory anti-inflammatory immunosuppressive state
Carvedilol, 419
CASS. See Coronary Artery Surgical Study
Cataract surgery, 38, 373, 376
CBC. See Complete blood count
CBT. See Cognitive behavioral therapy
CCEC. See Conventional cardiopulmonary bypass circuits
CDC. See Centers for Disease Control
Celebrex, 223r
Celecoxib, 219, 223r, 224, 525
Celexa, route of administration and dose ranges, 234r
Celiac disease, 151
Cell saver technique, 294
Center for Substance Abuse Treatment, 243
Centers for Disease Control, 149–150, 256
Centers for Medicare and Medicaid Services, 17, 24, 29, 31, 35, 86, 481
  Surgical Infection Prevention Collaborative, 487, 493
Central fever, 346
Central pattern generator, vomiting and, 425, 426, 426
Cerebral aneurysms, 207, 348
Cerebral edema, normal brain vs., computed tomography images, 343
Cerebral perfusion pressure (CPP), 327, 342
Cerebral salt wasting, 343, 344
  SIADH vs., 345r
Certolizumab, 226, 226r
Cervical spine subluxation abnormalities, rheumatoid arthritis and, 216
Cesarean section
  hypertension and, 262
  maternal risks with, 260
  pulmonary emboli and, 262
  septic pelvic thrombophlebitis and, 263
CET. See Cardiopulmonary exercise testing
Change pathway, 21, 22, 22
Charlson Index, for comorbidities, 441
Chemical dependency, 240–243
  behavior management, 243
  general considerations, 240–242
  medication management, 242–243
  signs/symptoms of intoxication and withdrawal, 241r
Chemoreceptor trigger zone, 426, 426, 427
Chemotherapy, 269
  cardiovascular conditions in cancer patients and, 269
  pulmotoxic chemotherapeutic drugs, 272r
  renal side effects of, 273r
  for soft tissue sarcomas and osteosarcomas, 315r
Chest radiography, 35, 38, 43–44, 119, 120, 127
CHF. See Congestive heart failure
Chief complaint, 87
Child-Turcotte-Pugh (CTP) score, 152, 152r, 153, 157
Chlorambucil, pulmotoxicity and, 272r
Chlordiazepoxide, 156, 232, 242, 243
Chlorpromazine, 237, 238, 239, 431
Cholecystectomy, 170–171, 251, 257
Cholecystitis, postoperative fever and, 455, 457r
Cholestyramine, 225
Cholinergic antagonists, PONV management and, 430
Chronic kidney disease, 185
  anemia and, 197
  cardiovascular evaluation and, 189–191
  electrolyte management with, 195–197
  epidemiology, 185–186
  fluid management and, 192
  gout and, 222
  nutritional status and, 197
  prediction of risk for patients with, 186
Chronic medications, stopping, for surgical procedure, 48
Chronic obstructive pulmonary disease, 117, 118, 291, 292, 301, 302, 313, 341, 377
past medical history, 36
physical exam, 38
postoperative acute kidney injury and, 502
Cigarette smoking, past medical history, 36
Cimzia, 226
Cirrhosis, 151, 152, 178
hepatitis C-related, 156
narcotics, sedative use and, 156
postoperative mortality in patients with, 154
surgical risk for patients with, 153, 155
Cisplatin
renal side effects of, 273
for soft tissue sarcomas and osteosarcomas, 315
Citalopram, 57, 234
CIWA-Ar. See Clinical Institute Withdrawal Assessment for Alcohol-revised
CKD. See Chronic kidney disease
Clean surgical procedure, 485
Clean-contaminated surgical procedure, 486
Cleveland Clinic, 63, 64, 187, 503
Clindamycin, 318
Clinic managers, hiring, 70
Clinical Institute Withdrawal Assessment for Alcohol-revised, 242, 247–250
Clinical prediction rules, 120–122
Clomipramine, 57
Clonazepam, 232
Clonidine, 52, 243, 347
Clopidogrel, 49, 50, 205
neuraxial blockade, cautionary note, 181
Clostridium difficile infection, postoperative fever and, 454–455, 457, 459
CMS
consultation destination codes, 2010, 91
documentation guidelines, 87
redistribution of consultation codes and, 90, 92
Coagulase-negative staphylococci (CoNS), 487, 488, 491
Coagulation abnormalities, genetic, 174
Coagulopathy, trauma-induced, 335–336
Cocaine cessation, 242
Cockcroft-Gault equation, 193, 199
Code team, medical consultation service, 76
Codeine, 525, 529, 532
Coding, perioperative medicine and, 89–90, 92
Cognitive behavioral therapy, 233
Cold antibodies, AIHA and, 172, 173
Colonic ileus, 304
Coma, 327
Co-management, 8–9
addressing financial implications of, 17
consultation vs., 81–82
defined, 11
development of arrangements with, 11
elements of successful programs, 14–19
ask the tough questions, 14, 15–16
clarify roles and responsibilities, 14, 16–17
identify stakeholders and define their expectations, 14, 15
measure performance, 14, 18
obtain resources and support, 14, 17–18
revisit the relationship, 14, 18–19
medical consultation service, 76
Co-management of surgical patient, 11–19
evidence, 12
risk and benefits, 12–14
career dissatisfaction, 14
complexity, 13
inconsistent delivery, 13
scope of practice, 13
understaffing, 14
Communication
effective, medical consultation and, 6
for preoperative clinics, 70–71
standards for medical consultation service, 77–78
Comorbidities, review of systems, 37
Compensatory anti-inflammatory immunosuppressive state, 390
Complete blood count, 165
Complete ROS, 88
Comprehensive (Comp) physical examination, 88
Compression stockings, 351, 465
Compression ultrasonography, 471, 473, 474, 476
Computer tomographic pulmonary angiography, 475, 476
Confusion assessment method (CAM), 317, 441, 442, 444, 445, 446, 449
Congenital anomalies, 256–257
Congestive heart failure, 36, 37, 118, 313, 418–421
  background, 418–419
  medical management, 421
  pathophysiology, 419
  postoperative acute kidney injury and, 502
  postoperative assessment, 420–421
  prevention strategies, 419–420
Consta, 57
Consultation codes
  CMS and redistribution of, 90, 92
Consumers Union, 32
Contaminated surgical procedure, 486
Continuous positive airway pressure, 124, 304
Continuous renal replacement therapy (CRRT), 509
Conventional cardiopulmonary bypass circuits, 295
Coombs test, direct and indirect, 165
COPD. See Chronic obstructive pulmonary disease
Coronary artery bypass grafting, 285, 286, 287, 289, 290, 291, 293, 294, 410
Coronary artery disease, 97
  assessment of comorbidities, 99
  clinical history, important elements, 98–100
  evaluating extent/stability of, 99
  evaluating patients with CKD and, 190
  functional status assessment, 99–100
  perioperative quality indicators, 110
  perioperative testing, 100–101
  physical examination, 100
  review of prior surgical interventions/comlications, 99
Coronary Artery Surgical Study, 106
Coronary bypass surgery, reducing PPC rates after, 125
Coronary revascularization, ACC/AHA Guidelines, 410
Corticosteroids (CSs), 54–55, 55r, 146
  rheumatologic disease and, 224–225
  Surviving Sepsis Campaign Guidelines for, 398, 399r
Corticotropin-releasing hormone, 54
CORTICUS trial, 398
Cost-containment measures, 85
COURAGE study, 106
CPAP. See Continuous positive airway pressure
CPG. See Central pattern generator
CPRs. See Clinical prediction rules
CPT codebook, sections in, 86
CPT codes
  choosing, E/M services, 89, 89r
  health insurance coverage and, 90
  recommendations for, 41t
Cr, preoperative lab testing, 41t
Craniotomy, 340, 341
Creatinine, 36
Creatinine clearance
  estimating, 193
  hip fracture patients and, 314
CREST syndrome, 222
CRH. See Corticotropin-releasing hormone
Cricoarytenoid joints, rheumatoid arthritis and, 216
“Crossing the Quality Chasm: A New Health System for the 21st Century,” 21
CSAT. See Center for Substance Abuse Treatment
CSW. See Cerebral salt wasting
CT coronary angiography, 363r
CTPA. See Computer tomographic pulmonary angiography
CTZ. See Chemoreceptor trigger zone
CURE trial, 205
CUS. See Compression ultrasonography
Cyclophosphamide
  pulmotoxicity and, 272t
  renal side effects of, 273r
Cyclosporine, perioperative infection and, 303
Cytosine arabinoside (ARA-C), pulmotoxicity and, 272t
Dabigatran, 468
Dacryocystorhinostomy, 380
Dalteparin, 60, 180
DAMPs. See Danger-associated molecular patterns
Danaparoid sodium, 179
Danger-associated molecular patterns, 388
Dantrolene, 456
Dasatinib
cardiotoxicity and, 270
pulmotoxicity and, 272
Daunorubicin, cardiotoxicity and, 270
DBPs. See Diastolic blood pressures
D-dimer testing
for DVT, 473
for pulmonary embolism, 475–476
DECREASE studies, 101
DECREASE-I study, 106
DECREASE-III study, 108
DECREASE-IV study, 205
DECREASE-V study, 106
Deep breathing exercises, 124, 302, 304
Deep incisional surgical site infections, 486
Deep venous thrombosis, 18, 29, 316, 351, 358, 364, 463, 465
assessment of, simplified clinical model for, 474
clinical prediction rules for, 473
diagnosing, 471, 473–474
algorithms for, 473–474, 474
prophylaxis, post-cesarean section, 262
Delirium, 439–449
causes of, 439
Confusion Assessment Method, 442
high-risk medications in patients predisposed to, 443
medical management, 446–448
managing agitation, 447–448
nonpharmacologic therapy, 447–448
pain management, 446–447
Mini-Cog score, 442
in neurosurgery patient, 351–353
orthopedic surgery and, 317–318
pain management issues and, 320
pathophysiology, 439–440
post-op assessment, 445–446
acute onset and fluctuating course, 445
altered level of consciousness, 446
disorganized thinking, 446
inattention, 445–446
prevention strategies, 440–445
cognitive risk factors, 442–443
intraoperative risk factors, 443–444
modifiable risk factors, 441, 442
nonmodifiable risk factors, 440–442
pharmacologic risk factors, 443
prophylactic therapy, 444–445
risk factors and approach to, 318
treatment of, 447
Delirium tremens (DTs), 240, 243, 331
Dementia, delirium and, 317
Depacon, 57
Department of Veterans Affairs, National Surgical Quality Improvement Program, 121–123
Depression, 240
bipolar, 233
unipolar, 233, 234–236
Dermatomyositis, 221
Desflurane, 155, 440
Desmopressin, 175, 294
DESs. See Drug-eluting stents
Detailed (Det) physical examination, 88
Detemir, 133, 135
Dexamethasone, 429, 430, 433, 434, 435
Dexmedetomidine, 329
Diabetes, 36
cancer patients with, 272–273
general overview of postoperative management of, 139
history, 131–132
medications for, 53–54
ophthalmic surgery and patients with, 379
perioperative setting and, 131
post CABG, 293
postoperative management of, evidence base for, 135–144
current glycemic control, 138
glycemic management, 137
ill/unstable patients, 137
IV insulin, 141
matching nutritional insulin with nutritional intake, 139–141
oral diabetes medications, 138
patient nutrition, 137–138
sliding-scale insulin, 141
special nutritional circumstances, 141
subcutaneous insulin, 138–139
transitioning from inpatient to outpatient regimen, 141, 143–144
preoperative management of, 132–135
insulin, 133–135
oral diabetes medications, 133
successful management of, 132
surgical site infections in patients with, 493
testing, 132
Diabetes mellitus, 151
bariatric surgery patient and, 365–366
epidemiology, 131
post-bariatric surgery management, 367–369
postoperative acute kidney injury and, 502
Diabetic ketoacidosis, 134
Diagnostic related group, 18
Diagnostic testing, anemia, 165–167
Dialysis, 509, 510
after cardiac surgery, AKI and, 503, 504
Dialysis patients, 185, 186
anesthetic considerations for, 191
cardiac disease in, 190
intensive care support for, 195
ophthalmic surgery and, 378
perioperative management of, 192–193
Diastolic blood pressures, 38
Diazepam, 156, 232t, 241
Diclofenac, 223t
Digoxin, 52
Direct revenues, preoperative consultations,
diagnostic testing and, 64
Dirty surgical procedure, 486
Discharges for surgical proceedings, by age
group, change in number of, 98
Disopyramide, 52
Disseminated intravascular coagulation
(DIC), 166
Distraction vests, 448
Diuretics, 52, 420, 421, 507–508
DKA. See Diabetic ketoacidosis
dobutamine stress echo with contrast
agents, 363t
dobutamine stress echocardiography, 107
docetaxel
cardiotoxicity and, 270t
ischemia and, 271t
documentation, preoperative consultative
services and, 87–89
dolasetron, 428, 429, 430, 434
donepezil, 444
dopamine, low-dose, 507
dopamine antagonists, PONV management
and, 430–431
doxacurium, 155
doxorubicin
cardiotoxicity and, 270t
pulmototoxicity and, 272t
for soft tissue sarcomas and
osteosarcomas, 315t
droperidol, 431, 433
droperidol IV, 429t
drug withdrawal, 240, 456
drug-eluting stents, 50
SFAR recommendations of oral
antiplatelet therapy in patients
undergoing surgery, 51t
drug-related fever, in neurosurgical patient,
346
Drugs in Pregnancy and Lactation, 258
Duchenne muscular dystrophy, 210–211
DVT. See Deep venous thrombosis
dysautonomia, incidence of, 346
Early goal-directed therapy, protocol for,
395
EBITDA analysis, 69
echinacea, pharmacologic effects and
perioperative management
recommendations for, 56t
Echocardiography
ACC/AHA guidelines, 277
for bariatric surgery patient, 362
ECT. See Electroconvulsive therapy
EDTA. See Ethylenediaminetetraacetic acid
EKG
intracranial pathology and changes in,
347
postoperative monitoring, for ST-segment
changes, 109
Electrocardiograms (ECGs), 35, 38
for bariatric surgery patient, 361–362
preoperative setting, 40–43
ACC/AHA recommendations, 42, 43t
ASA guidelines, 42
Brigham and Women’s Hospital study,
42
Canadian university hospital studies,
41
Netherlands study, 40–41
Electroconvulsive therapy, 231, 244–245
general considerations, 244
medication management, 245
patient-focused management, 244–245
Electrolyte management, 195–197
  acidosis, 196
  anemia and bleeding diathesis, 197
  calcium and phosphate, 196
  hyperkalemia, 195–196
  hypertension and hypotension, 196–197
  nutrition, 197
Electrolytes, preoperative lab testing, recommendations for, 41
E/M services, choosing CPT code, 89, 89
Emend, 432
Enbrel, 226
Endocrine diseases, risk assessment and management for noncardiac surgery, 131–146
Endogenous pyrogens, 451
Endometritis, postpartum, 263
End-stage renal disease (ESRD), 178
ENHANCE trial, 401
Enhanced Feedback for Effective Cardiac Treatment study, 27
Enoxaparin, 59, 60, 60, 180
Enteral nutrition, 141
Ephedra, pharmacologic effects and perioperative management recommendations for, 56
EPIC trial, 409
Epidural analgesia, 526–527, 535
Epirubicin, cardiotoxicity and, 270
Epworth sleepiness scale, 360, 364
Erlotinib, ischemia and, 271
Erythropoietin, treatment, anemia of chronic disease and, 169–170
ESC. See European Society of Cardiology
Escherichia coli, surgical site infections and, 487
Escitalopram, route of administration and dose ranges, 234
Etanercept, 226, 226
Ethylendiaminetetraacetic acid, 178
Etodolac, 223
Etoposide, pulmotoxicity and, 272
European Society of Cardiology, 50, 478
Euvolemia, in patients with CKD, 192
Exenatide, 54, 133
Expanded problem focused (EPF) physical examination, 88
Expenditures in health care, surgical expenditures, 85
Extended ROS, 88
Facility design/outfitting, at University of Miami preoperative clinic, 67–68
Factor II deficiency, 175
Factor V deficiency, 175
Factor VII deficiency, 175–176
Factor XI deficiency, 177
Falls, classification of, 313
Family history, 37
Fasting glucose level, 132
Fat embolism, 311, 457, 457
FDA. See Food and Drug Administration
Fee-for-service basis, Medicare and, 85
Feldene, 223
Femoral neck fractures, 311
  right, pre- and postoperative views of, with subsequent hemiarthroplasty, 312
Femur fracture, left intertrochanteric, pre- and postoperative views of, and subsequent dynamic hip screw, 312
Fenoldopam, 507
Fentanyl, 329, 447, 522, 523–524, 525, 526, 531
Ferric gluconate, 168
Ferritin, 166
Fetal heart rate (FHR) monitoring, 261
Fetal radiation exposure, estimated, related to maternal radiological studies, 255
FEV1, 117
Fever
  in neurosurgical patient, 345–347
  peripartum, 263–264
Fever, postoperative, 451–460
  background, 451
  infectious causes of, 457
    cholecystitis, 455
    Clostridium difficile infection, 454–455
    pneumonia, 454
    surgical site infection, 453–454
    urinary tract infection, 454
  investigation of patient with, 458–459
  medical management, 459–460
  noninfectious etiologies
    adrenal insufficiency, 456–457
    drug reaction, 456
drug withdrawal, 456
gout, 456
malignant hyperthermia, 456
other types of, 457
venous thromboembolic disease, 455
pathophysiology, 451–452
postoperative assessment, 452–453
prevention strategies, 459
serious/life-threatening causes of, 453
Flail chest, 330
Flecainide, 52
Fludarabine, pulmotoxicity and, 272
Fluid management, for patients with CKD, 192
Fluid resuscitation, in sepsis, goal of, 394
5-Fluorouracil (5-FU), ischemia and, 271
Fluoxetine, route of administration and dose ranges, 234
Fluphenazine, 57, 238
Fluvastatin, 108, 109
Focus groups, nonmedical services, 80, 80
Folate-deficiency anemia, 168
Folic acid, for alcohol-dependent patients, 242
Fondaparinux, 179, 180, 316, 364
Food and Drug Administration, 55, 233, 258
Forced expiration techniques, 125
Forced expiratory volume, 117, 119
Fosphenytoin, 326, 328
FRC. See Functional residual capacity
French Society of Anesthesiology and Intensive Care, oral antiplatelet recommendations of, 51
Fresh frozen plasma (FFP), 175
Functional capacity, assessing, 37
Functional residual capacity, 254, 362
Functional status, assessment of, 99
Funding, for medical consultation services, 78–79
Furosemide, 192, 508
Gabapentin, 232, 233, 347
Gaming, 29
Garlic, pharmacologic effects and perioperative management recommendations for, 56
Gasless laparoscopy, 260
Gastric bypass surgery, glomerular filtration rate and, 501
Gastric sleeve, 357, 358
Gastrointestinal (GI) complications after cardiothoracic surgery, 295–296
ischemic bowel, 296
lower GI bleeding, 295–296
upper GI bleeding, 295
Gefitinib, cardiotoxicity and, 270
Gemcitabine
ischemia and, 271
pulmotoxicity and, 272
General anesthesia, PPC risk and neuraxial blockade vs., 125
Generalized anxiety disorder, 231
Geneva rule, for pulmonary embolism, 476
Geodon, route of administration and dose ranges, 234
Geriatric patients
pain control for, 522
preoperative guidelines and, 39
GFR. See Glomerular filtration rate
Gingko, pharmacologic effects and perioperative management recommendations for, 56
Ginseng, pharmacologic effects and perioperative management recommendations for, 56
Glargine, 54, 133, 135
Glasgow coma scale (GCS), 327, 346
Glomerular filtration rate, 186, 187, 500, 501, 502, 510
estimating, 193
pregnancy and, 252
GLP-1 agonists, 54
Glucontrol study, 402
Glucontrol study, 402
Glucontrol study, 402
Glucose, preoperative lab testing, recommendations for, 41
Glucose control, Surviving Sepsis guidelines for, 403
Glucose intolerance, liver disease and, 150
Glucose testing, 132
Glucose-6-phosphate dehydrogenase (G6PD) deficiency, 174
Glulisine, 133
Glycemic control
baseline, 131
for neurosurgery patient, 350–351
sepsis and, 401–402
for trauma patients, 332
Glycemic goals, summary of, and methods for achieving, 137
Glycemic management
  goals of, 53
  postoperative, overview of, 137
Glycemic monitoring, at home, 144
Glyco-protein IIb/IIIa inhibitors, 50
Goldman risk score
  clinical parameters and risk points, 103
  derivation of, 101
  postoperative outcomes based on, 103
Golimumab, 226, 226t
Gout
  postoperative, 222–223
  postoperative fever and, 456, 457, 457t
Graduated compression stockings (GCSs), 465
Granisetron, 428, 429, 430, 434
Grave’s disease, 146
Gross domestic product, surgical expenditures as percentage of, 85
Group A Streptococcus, 455
Guided imagery, 233
Hageman factor (factor XII) deficiency, 177–178
Haloperidol, 57, 237, 238, 239, 352, 353, 431, 444, 445, 448
Haloperidol IV, 429t
Halothane, 155
HbA1c levels
  characterizing baseline glycemic control and guide management postoperatively, 143
  measuring, 143–144
HCPCS. See Healthcare Common Procedure Coding System
HCUP. See Healthcare Cost and Utilization Project
Health insurance coverage, CPT codes and, 90
Health Insurance Portability and Accountability Act, 78, 86
Health outcomes, assessing quality of care and, 23
Healthcare Common Procedure Coding System, 86
Healthcare Cost and Utilization Project, 386
Healthcare costs, reducing, transparency programs and, 28
Healthcare reform, physician reimbursement and, 92
Healthgrades, 25t
Heart block, 414–415
Heart failure, prescribing medications perioperatively, 420
Heart rate and rhythm, 288
Heart-rate reduction, perioperative events and, 107
Heat stroke, 451
Hematological complications
  cardiothoracic surgery and, 293–295
  anemia, 293–294
  hemolysis, 294–295
  thrombocytopenia, 295
Hematomas, postoperative fever and, 457, 457t
Hemodialysis, 190
Hemodynamic agents, 507–508
Hemoglobin, preoperative lab testing, recommendations for, 41
Hemoglobin A1c level, 131
Hemolysis, 294–295
Hemolytic anemia, 166
Hemolytic uremic syndrome (HUS), 166
Hemophilia, 151, 176–181
  factor XI deficiency, 177
  Hageman factor (factor XII) deficiency, 177–178
  neuraxial blockade, special considerations, 180–181
  thrombocytopenia, 178–179
  thrombocytosis, 180
  thrombophiliias, 180
Hemophilia A, 176–177
Hemophilia B, 177
Hemostatic abnormalities, 163
Hemostatic function, evaluating, 173
Heparin
  dialysis patients and, 192–193
  unfractionated, 59
Heparin-induced thrombocytopenia (HIT), 179, 295, 332, 468
Hepatitis B, Asian immigrants and, 149
Hepatitis C-related cirrhosis, 156
Hepatobiliary system, 149–159
  algorithm for preoperative evaluation, 150
American Society of Anesthesiologists classification, 154, 154t
diagnostic testing, 151–152
epidemiology, 149
liver transplantation, 156–158
medical history, 149–151
minimizing risk, 158
physical examination, 151
postoperative management, 158–159
predicting risk, 152–156
Hepatotoxicity, drug-induced, 151
Herbal medications, 55, 56t
Heroin, detoxification and, 243
HFSs. See Hip fracture surgeries
Hgb, preoperative checking, 165
Hgb electrophoresis, 166
High blood pressure. See Hypertension
Hip arthroplasty, sickle-cell disease and, 171
Hip fracture surgery (HFS), 309
delirium and, 317, 318
preoperative assessment, 313–314
risks associated with, 311
thromboprophylaxis and, 469
Hip fractures
fatal pulmonary embolism and, 351
incidence of, 309
Hip replacement, thromboprophylaxis and, 469
HIV infection, 151
HMG CoA reductase inhibitors, 53, 205
HMGs. See Hospital medicine groups
Hospital Compare, 24, 25t
Hospital Medicine
co-management integral to, 11–12
understaffing and, 14
Hospital medicine groups, co-management and, 11
Hospital selection, transparency initiatives and limited effects on, 26
Hospitalist co-management, mission creep and, 13
Hospitalists, 3
clarifying roles and responsibilities of, 16–17
involvement of, in neurosciences, 339
role of, 3, 7
co-management and, 12
expanding, 75
Hospitals, bundled payments for, 92
HPI. See History of present illness
5-HT3 receptor antagonists, 428–430
HTN. See Hypertension
Human resources, for preoperative clinics, 70
Humira, 226t
Hyaline casts, 193
Hydrocodone, 525t, 532
Hydromorphone, 329, 447, 521, 525, 525t, 526, 528, 529, 532
Hydroxychloroquine, 226, 378
Hypercoagulability, 180
Hyperglycemia, 134, 136, 401
cancer patients with, 273
control of, recommendations for, 53
epidemiology, 131
IV insulin infusions and, 141
management of, in postoperative setting, 135–136
general overview, 139t
in neurosurgery patient, 350
patient education, 144
perioperative setting and, 131
testing, 132
transition from inpatient to outpatient medical regimen, 141, 143–144
Hyperkalemia, 191, 193, 195–196
Hypernatremia, 193
Hypertension, 38
  in bariatric surgery patients, 360
  in CKD patients, 196–197
  in neurosurgery patients, 342, 349–350
  ophthalmology surgery and, 375
  post-bariatric surgery and, 366
  pregnant surgical patients and, 262–263
Hyperthermia, malignant, 451, 456
Hyperthyroidism, perioperative management of, 146
Hypocalcemia, 196
Hypoglycemia, 53, 131, 132, 133, 134, 137, 138, 139, 332
Hyponatremia, 193, 342–345
Hypotension, in CKD patients, 196–197
Hypothalamic-pituitary-adrenal (HPA) axis sepsis and, 397
  stress response in perioperative period and, 54
Hypothyroidism
  perioperative management of, 145–146, 145r
  surgical outcomes and, 144–145
Hypoxemia, 133
Hysterectomy, abdominal, postoperative ileus and, 304, 305
Ibuprofen, 223r, 346
ICDs. See Implantable cardioverter-defibrillators
IDA. See Iron-deficiency anemia
Idarubicin, cardiotoxicity and, 270r
Idiopathic thrombocytopenic purpura, 179
IFIS. See Intraoperative floppy iris syndrome
Ifosfamide
  renal side effects of, 273r
  for soft tissue sarcomas and osteosarcomas, 315r
Ileus, postoperative, 304–305
Imaging
  pregnancy and, 256
  rheumatoid arthritis, 217
Imatinib
  cardiotoxicity and, 270r
  pulmotoxicity and, 272r
Imipramine, 57
Implantable cardioverter-defibrillators, 232, 376
Incentive spirometry, 124, 302, 304
Incretin enhancers, 54
Indirect revenues, preoperative clinics, 63–64
Indocin, 223r
Indomethacin, 219, 223r
Infection, proposed action of activated protein C and, 400
Infectious Diseases Society of America, 28
Inflammatory bowel disease (IBD), 301, 302–303
Infliximab, 226, 226r
Information systems, at University of Miami preoperative clinic, 68
Injury, as leading cause of death in U.S., 325
Inspiratory muscle training, 124, 125, 127
Institutional needs, for medical consultation service, 75–76
Insulin, 54
  basal-bolus, 133, 139, 144
  intermediate/long-acting, 133–134
  IV infusion, postoperative management of, 141
  nutritional, matching with nutritional intake, 139–141
  premixed, 134–135, 135r
  preoperative management of, 132–135
  short/rapid-acting, 133, 134
  sliding scale, use of, 141
  Society of Hospital Medicine Glycemic Control Task Force recommendations, 141, 142r
  subcutaneous, postoperative management of, 138–139
  total daily dose of, 140
Insulin pump, 135r
Insulin secretagogues, 133
Insulin survival skills, 144
Insulin therapy
  in neurosurgical setting, 350–351
  post-surgery, Roux-en-Y gastric bypass, 367–368
  sepsis and, 401–402
Interleukin-18 (IL-18), 507
Intermediate/long-acting insulins, management guidelines, on day of surgery, 135r
Intermittent pneumatic compression (IPC) devices, 465
Intermittent positive pressure breathing, 304
Kidney injury. See also Acute kidney injury postoperative, 499–512
in trauma patients, 332–333
Kineret, 226t
King’s College Hospital, liver transplantation criteria, 156, 157t
Klonopin, 232t
Knee replacement, thromboprophylaxis and, 469
Knodell Histology Activity Index, 151
Kytril, 428
Labetalol, 262
Labor, preterm, laparoscopy vs. laparotomy, 258–259
Laboratory testing, 39–40
ankylosing spondylitis/psoriatic arthritis, 219
cardiac surgery, 286
hepatobiliary system, 151
peripartum fever and, 263
rheumatoid arthritis, 217
selective preoperative, recommendations for, 41t
systemic lupus erythematosus, 221
Lactic acidosis, 133
Laparoscopic gastric band (LAGB), 357, 358
Laparoscopy vs. laparotomy, minimizing risk in pregnant patient and, 258–259
Leapfrog Group, 25t
online posting of hospital ratings based on surgical volumes for high-risk procedures, 23, 23
Lee’s Revised Cardiac Risk Index, 104t
Leflunomide, 225–226
Length of stay, hospital co-management and, 12, 18
Lens extraction, 373
Levobupivacaine, 526
Levosimendan, 421
Levothyroxine, 145, 146
Lexapro, route of administration and dose ranges, 234t
Librium, 232t
Lines of responsibility, for medical consultation service, 77
Lispro, 133
Listeria, 263
Lithium carbonate, 236
Liver disease
  absolute contraindications to elective surgery in patient with, 153, 153t
  chronic, ethnicity and, 149
  postoperative management of, 158–159
  predicting risk in patients with, 152–156
  underlying, clues for, 150–151
Liver failure, acute, 156
Liver transplantation, 156–158
  contraindications for, 157–158, 158t
  fundamental goals of, 156
  indications for, 156t
  King’s College criteria, in fulminant hepatic failure, 157t
LMWH. See Low-molecular-weight heparin
Lodine, 223t
Long QT syndrome, 414
Loop diuretics, 192, 421
Lorazepam, 155, 232, 232t, 242, 329, 331, 445
LOS. See Length of stay
Low-molecular-weight heparin, 332
  bridging therapy and, 59
  contraindicated with HIT, 179
  in neurosurgical setting, 351
  perioperative bridging strategy, 60
  pregnancy and, 262, 264
  thromboprophylaxis and, 364–365, 468
  VTE prophylaxis and, 305, 316
Lung expansion maneuvers, 124, 126, 302, 304
Ma huang, pharmacologic effects and perioperative management recommendations for, 56t
Macrocystic anemia, 166
Major depression, 233
Malignant hyperthermia (MH), 379, 451, 456
Manic depressive illness, 233–234
Mannitol, 328
MAO. See Monoamine oxidase
MAOIs. See Monoamine oxidase inhibitors
Market share, public reporting and impact on, 27
Maternal mortality, perioperative, primary cause of, 257–258
MCV. See Mean corpuscular volume
MDM. See Medical decision making
Mean corpuscular volume, obtaining, 165, 166
MECC. See Minimized extracorporeal circulation
Mechanical falls, 313
Mechanical ventilation, prolonged, after cardiac surgery, 291–292
Medical consultation, 3
  advantages of, 4
  general principles of, 4–7
Medical consultation service
  bricks of foundation for, 76t
  collaboration vs. co-management, 81–82
  collaboration with nonmedical services, 79–81
  anesthesiology, 81
  orthopedic surgery, 80–81
  other nonmedical specialties, 81
  surgical specialties, 80
  communication standards, 77–78
  coordination with preoperative evaluation clinic, 82
  developing, implementing, and operating, 75–84
  expectations and lines of responsibility, 77
  funding, 78–79
  institutional needs for, 75–76
  measurement of success for, 83–84
  midlevel care providers and trainees, role of, 82–83
  standardized order sets, 78
  types of services provided with, 76–77
Medical decision making, levels of, 88–89, 88t
Medical decision-making component, 88t
Medical directors, for medical consultation services, 78
Medical falls, 313
Medical management, in orthopedic surgery, 317
Medicare
  bundled payments and, 92
  CPT codes and, 90
  Part B, 86
  RBRV system and, 85–86
Medicare Payment Advisory Commission (Medpac), 92
Medicare secondary payers (MSPs), 90
Medication management, perioperative, 47–61
anticoagulation management, 57–61
antiplatelet agents, 48–50
background on, 47
cardiovascular medications, 50, 52–53
corticosteroids, 54–55, 55t
diabetes medications, 53–54
general guidelines for, 48
herbal medications, 55, 56t
psychiatric medications, 57
pulmonary medications, 53
relevance, 47–48

Medications
febrile reactions to, 456
history, 36
oral diabetes
postoperative management of, 138
preoperative management of, 132–135

Meditation, 233
Meglitinides, 133
Meperidine, advanced kidney disease and, avoidance of, 191
6-mercaptopurine, perioperative infection and, 302
Mesalamine, perioperative infection and, 302
Metabolic equivalents (METs), 37, 99
Metabolic syndrome, liver disease and, 150
Metacarpophalangeal (MCP) arthropathy, 151
Metformin, 53, 133
Methadone, 243, 520, 525t
Methicillin-resistant S. aureus (MRSA), surgical site infections and, 491, 495
Methotrexate, 225, 378
pulmotoxicity and, 272t
renal side effects of, 273r
for soft tissue sarcomas and osteosarcomas, 315t
Methyldopa, 262
Metoclopramide, 429t, 431
Metolazone, 192
Metoprolol, 108, 235
Metoprolol (sustained release), 419
METs. See Metabolic equivalents
MI. See Myocardial ischemia/myocardial infarction
Microcytic anemia, 166
Microsoft Project, 69
Midazolam, 191, 329
Midlevel care providers, medical consultation service and, 82–83
Miglitol, 133
Mini-Cog score, delirium and, 441, 442t, 445
Mini-Mental State Examination, 444, 446
Minimized extracorporeal circulation, 294
Mirtazapine, 57, 235
route of administration and dose ranges, 234t
Mission creep, hospitalist co-management and, 13
Mitomycin, pulmotoxicity and, 272t
Mitoxantrone, cardiotoxicity and, 270t
Mitral valve replacement, 285
MMSE. See Mini-Mental State Examination
Model for End-Stage Liver Disease (MELD) score, 152, 153, 154, 158, 159
MODS. See Multiple organ dysfunction syndrome
Monoamine oxidase, 57
Monoamine oxidase inhibitors, 235, 236
Monopolar depression, 233
Mood disorder, 233–237
behavior management, 237
general considerations, 233–234
medication management, 234–237
bipolar affective disorder, 236–237
unipolar depression, 234–236
Morbidity and mortality after surgery, greatest sources of, 115
atrial fibrillation, 289
cardiac surgery, 287
cardiovascular, chronic kidney disease and, 190
delirium, 439, 449
dialysis patients, 185
hip fractures, 309, 311
perioperative cardiac events, 97
postoperative AKI and, 195
sepsis and septic shock, 387
substance abuse, 240
surgical site infections, 496
Morphine, 329, 347, 447, 522, 525, 525t, 526, 528, 529t, 531, 532
acute postoperative pain and use of, 524
IV-PCA therapy and, 528
renal failure patients, cautionary notes, 191
Motrin, 223t
Multidrug resistance, surgical site infections and, 487, 493, 495
Multiple organ dysfunction syndrome, 399
Multiple sclerosis, 208–209
Multivitamins, for alcohol-dependent patients, 242
Muscular dystrophy disorders, 210–211
MVR. See Mitral valve replacement
Myasthenia gravis, 209–210
Mycofenololate, 226
Myocardial ischemia/myocardial infarction
background, 407–408
medical management, 411–412
pathophysiology, 408
postoperative assessment, 410–411
prevention strategies, 408
coronary revascularization, 410
medication management, 408–410
Myocardial perfusion imaging, 363t
for bariatric surgery patient, 362
Nabumatone, 223t
N-acetylcysteine, 508–509
Naprosyn, 223t
Naproxen, 223t
Nasogastric tube, 125, 126, 127, 305
National Comprehensive Cancer Network,
277, 478
National Healthcare Safety Network,
surgical site infection definitions,
485, 486t
National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy, 262
National Osteoporosis Foundation, 319
National Patient Safety Goals, 494
National Surgical Improvement Program, 386
National Surgical Quality Improvement Program, 32, 121–122, 122t, 357
Natriuretic peptides, 507–508, 510
Nausea. See also Postdischarge nausea and vomiting; Postoperative nausea and vomiting
mechanism of, 425–426, 426
NCCN. See National Comprehensive Cancer Network
Needs analysis, for medical consultation service, 75
Net present value, 69
Neuraxial anesthesia, in patient receiving anticoagulant therapy, 472t
Neuraxial blockade
PPC risk and general anesthesia vs., 125
special considerations with, 180–182
VTE prophylaxis, 469, 471
Neurocardiology, 347–349
Neurodegenerative disease, 208–211
Neurokinin-1 antagonists, PONV management and, 432
Neuroleptic malignant syndrome (NMS), 378
Neurologic complications
after cardiac surgery, 292–293
incidence, 292
prevention and treatment, 293
risk factors, 292–293
Neurosurgery, medical consultation and co-management, 339–353
Neurosurgical patient
anticoagulation, 351
challenges in perioperative care of, 339
delirium, 351–353
discharge recommendations/considerations, 353
fever: infection, central fever, and dysautonomia, 345–347
glycemic control, 350–351
hypertension, 349–350
hyponatremia and sodium management, 342–345
neurocardiology, 347–349
post-op assessment, 341–342
preoperative assessment, 340–341
surgery-specific risk, 340
venous thromboembolism prophylaxis in, 352t
Neurovascular disease, 201–207
cerebral aneurysms and arterial venous malformations, 207
perioperative stroke, 201–207
Neutrophil gelatinase-associated lipocalin, 507
New York State Cardiac Surgery Reporting System, 28
NGAL. See Neutrophil gelatinase-associated lipocalin
NHSN. See National Healthcare Safety Network
NICE-SUGAR trial, 136, 402
Nilotinib, pulmotoxicity and, 272
Nimodipine, 350
Noncardiovascular surgery incidence of AKI after, 500–501 outcomes in AKI after, 511 risk factors for AKI after, 504, 505
Nonmedical clinicians, questions to ask in focus groups with, 80
Nonmedical services establishing communication with, techniques for, 79 medical consultation program collaboration with, 79–81 anesthesiology, 81 orthopedic surgery, 80–81 surgical specialties, 80 Nonobstetric surgery, frequency and types of, 251
Non-ST-elevation MI (NSTEMI), 411, 412
NPO. See Nothing by mouth
NPs. See Nurse practitioners
NPV. See Net present value
NSAIDs. See Nonsteroidal anti-inflammatory drugs
NSQIP. See National Surgical Quality Improvement Program
Nucleus tractus solitarius (NTS), 426, 426, 428
Nurse practitioners, medical consultation services and, 83 Nutritional insulin, matching with nutritional intake, 139–141
Ophthalmic surgery, 373–380
common procedures, 373, 374
postoperative assessment, 379–380
surgery-specific risks, 373–374
Opioid abuse, detoxification and, 243
Opioids, 517, 532
for acute pain, principles of management for, 528
converting between morphine and other types of equianalgesic dosing, 524
delirium and, 447
pain relief with, medical management, 523–525
patients as opioid naive or opioid tolerant, determination for, 525
perioperative resistance to, 520
reducing side effects of, perioperatively, 525–526
repression depression and, 524
signs/symptoms of intoxication and withdrawal, 241, 241
peroperative assessment
oral diabetes medications, postoperative management of, 138
Orbital compartment syndrome, 379, 380
Order-writing privileges, for medical consultation service, 77
Orencia, 226
Organ/space surgical site infections, 486
Orthopedic oncology
preoperative assessment, 315
risks related to, 313
VTE prophylaxis and, 316–317
Orthopedic surgery, 215
medical consultation program and, 80–81
Orthopedic surgery, major, 309–321
arthroplasty, 309
postoperative assessment, 316–317
postoperative medical care
anemia, 320
delirium, 317–318
nutrition, 320
osteoporosis, 319
pain control, 320
rehabilitation, 320
renal function, 319–320
surgical site infection, 318
Oxazepam, 155, 156
Oxycodone, 522, 525, 528, 529
Pacemakers, 288
Paclitaxel
cardiotoxicity and, 270
ischemia and, 271
PAD. See Peripheral artery disease
Pain. See also Analgesia
  acute pain-response mechanisms and treatment opportunities, 518
  as “fifth vital sign,” 520
  postoperative, options available for, 519
  postoperative, reducing, 125
Pain, perioperative
  anticipating and managing, 517–532
  medical management, 523–532
  overtreatment of, adverse effects of, 517, 518
  pathophysiology, 518–519
  postoperative assessment, 522–523
  pain assessment questions, 523
  prevention strategies, 519–522
Pain control, for orthopedic surgery patient, 320
Pain management, delirium and, 446–447
Palonosetron, 428, 429
PAMPs. See Pathogen-associated molecular patterns
Pancuronium, 125
Panic disorder, 231
Paraspinal hematomas, reducing risk of, ASRA recommendations for, 180–181
Parenteral nutrition, 141
Parkinson’s disease, 208, 377
Paroxetine, route of administration and dose ranges, 234
Partial thromboplastin time, preoperative lab testing, recommendations for, 41
PAs. See Physician assistants
Past, family, and/or social history (PFSH), 88
Pathogen-associated molecular patterns, 388
Patient outcomes, improving, public reporting and, 21–22
Patient selection, reporting of healthcare quality and impact on, 24, 26
Patient-controlled epidural analgesic (PCEA) setup, 527
Paxil, route of administration and dose ranges, 234
PBC. See Primary biliary cirrhosis
PCI. See Percutaneous coronary intervention
PDNV. See Postdischarge nausea and vomiting
Pelvic ring injuries, 311
Pelvic surgery. See Intra-abdominal and pelvic surgery
Penicillin, 318
Pennsylvania Health Care Cost Containment Council, hospital-acquired infection rates report by, 23–24
Percutaneous coronary intervention (PCI), 293, 331, 408
Performance measurement, co-management and, 18
Perioperative medications, management of, 7
Perioperative systems, making sense of, 63–65
Peripartum fever, 263–264
Peripheral artery disease, 293
Peripheral blood smear, 165, 166
Peritoneal dialysis, 190, 193
PET, 363
PFT. See Pulmonary function testing
Phenothiazines, PONV management and, 430, 431
Phenylephrine, 57
Phenytoin, 326, 328, 346
Phosphate, 196
Physical examination, 37–38, 39
  anemia, 164–165
  ankylosing spondylitis/pсорiatic arthritis, 218
  bariatric surgery patients, 360–366
cancer patients and, 275–276
  cardiac surgery, 286
  cardiovascular, pregnancy and, 252–253
  coronary artery disease, 100
  levels of, 88
  liver disease, 151
  pulmonary risk assessment, 118–119
  rheumatoid arthritis, 216–217
Physical exercise programs, orthopedic surgery patient and, 320, 321
Physician assistants, medical consultation services and, 83
Physicians, bundled payments for, 92
Pioglitazone, 133
PIOPED study, 455
PIOPED II study, 474–475, 476
PIRO system for staging sepsis, 388, 389
Piroxicam, 223
Platelets, preoperative lab testing, recommendations for, 41
Pleural effusion, post CABG, 291
Pneumonia, 115
post CABG, 291
postoperative fever and, 454, 457 reducing rates of, 125
POISE trial, 108
POISE-2 trial, 410
Polymyositis, 221
PONV. See Postoperative nausea and vomiting
Positive end-expiratory pressure (PEEP), 327
Postdischarge nausea and vomiting, 425, 429
medical management of, 435
patient counseling about, 434
risk factors for, 426–427, 427t
Postoperative ileus (POI), 304
Postoperative nausea and vomiting, 425–435
antiemetic management strategies based on patient risk, 428
antiemetic medications, prophylactic, 427–432
cholinergic antagonists, 430
dopamine antagonists, 430–431
neurokinin-1 antagonists, 432
propofol, 432
serotonin antagonists, 427–430
steroids, 430
antiemetic techniques,
nonpharmacological prophylactic, 433
background, 425
combination therapy/multimodal management, 433–434
medical management of, 434–435
number needed to treat for common antiemetic regimens, 429t
pathophysiology, 425–426
post-op assessment, 434
prevention strategies, 427
risk factors for, 426–427, 427t
strabismus patients and, 379
Postoperative pulmonary complications, 115
abdominal and pelvic surgeries and, 301–302
predicting rates, strength of evidence for risk factors and lab test for, 121t
quality indicators and, 126, 127
reducing rates of, 125
risk factors for neurosurgery patient, 341
smoking cessation and rates of, 125–126
testing to estimate risk of, 119–120
Postoperative vomiting in children, 426
Posttraumatic stress disorder, 231
POVOC. See Postoperative vomiting in children
PPCs. See Postoperative pulmonary complications
Pramlintide, 133
Prasugrel, 49
Prednisone, 54, 224, 302
Preeclampsia, 262
Pregnancy
bariatric surgery and complications of, 369
diagnosis of surgical issues during, 254–255
laboratory changes in, 253t
physical exam and normal physiological changes of, 252–254
cardiovascular physical exam, 252–254
cardiovascular physiology, 252
renal physiology, 254
predicting risk during, 256–258
approach to prescribing, 258
congenital anomalies, 256–257
maternal complications, 257–258
obstetric complications (preterm labor/loss), 257
selection of medications during, 258
Pregnant surgical patients, 251–264
epidemiology, 251
history, 251–252
intraoperative issues, 260–261
abdominal CO2 insufflation, 260
anesthesia type, 260
avoid overresponding to contractions, 261
cesarean section, 260
fetal monitoring, 261
patient positioning, 261
perioperative collaboration, 260–261
plan of care as if woman is not pregnant, 261
laparoscopy vs. laparotomy, 258–259
pain control for, 522
postoperative care, 261–264
hypertension, 262–263
peripartum fever, 263–264
timing of surgery for, 259–260
Premixed insulins, 125r, 134–135
Preoperative centers, three models in use at, 64–65
Preoperative clinics
implementation at, 69–71
communications, 70–71
human resources, 70
project management, 69–70
project plan, 69
revenue cycle setup, 70
system integration, 70
implementing, sample project plan categories for, 72r
operations of, 71
successful, keys to, 71–72
Preoperative consultation, “rules of engagement” for, 87
Preoperative consultative services, documentation and, 87–89
Preoperative evaluation, 35–44
basics of, 36–38
CXR, 43–44
ECT, 40–43
history, 36–37
laboratory testing, 39–40
overview, 35–36
physical exam, 37–38
testing, 38–39
Preoperative evaluation clinic, medical consultation service coordination with, 82
Preoperative medical consult request, sample language for, 73r
Preoperative medical evaluation, 7
Preoperative testing, 38–39
Prerenal azotemia, renal azotemia vs., 194r
Preterm labor/loss, 257
Primary biliary cirrhosis, 150–151
Primary sclerosing cholangitis, 151
Problem focused (PF) physical examination, 88
Problem pertinent ROS, 88
Procaainamide, 52
Procarazine, pulmotoxicity and, 272r
ProCESS, 395
Processes of care, assessing quality of care and, 23
Prochlorperazine, 431, 435
Progressive relaxation, 233
Project management, for preoperative clinics, 69–70
Project plan categories, for preoperative clinic implementation, 72r
Project plans, for preoperative clinics, 69
Promethazine, 431, 435
ProMISE, 395
Propofol, 155, 191, 432
Propofol infusion, 429r
Propofol infusion syndrome, 329
Propranolol, 235, 347
Prosthetic devices, surgical site infections and, 485, 494, 495
Protein C levels
infection and, 400
PROWESS trial and analysis of, 400
Prothrombin time (PT), 174
preoperative lab testing, recommendations for, 41t
PROWESS trial, 400, 401
Proximal femur fractures, 311
Prozac, route of administration and dose ranges, 234r
PSC. See Primary sclerosing cholangitis
Psuedogout, 222
Psoriatic arthritis (PsA), 218–219
epidemiology, 218
examination, 219
history, 218–219
laboratory testing, 219
Psychiatric disease, 231–245
anxiety disorder, 231–233
chemical dependency, 240–243
mood disorder, 233–237
patient undergoing ECT, 244–245
psychotic disorder, 238–240
Psychiatric medications, 57, 61
Psychotic disorder, 237–240
behavior management, 239–240
general considerations, 237–238
medication management, 238–239
PT. See Prothrombin time
Ptosis surgery, 379
PTSD. See Posttraumatic stress disorder
PTT. See Partial thromboplastin time
Public reporting
change pathway and, 21, 22, 23
future directions, 31–32
of healthcare quality, 23, 23–24
impact on market share, 27
impact on patient selection, 24, 26
impact on referring providers, 27
methodological challenges in, measure selection, 30
problem with small sample and low event rates, 30–31
selection pathway and, 21, 22, 23
Pulmonary complications
abdominal and pelvic surgeries and, 301–302
ophthalmic surgery and, 377
postoperative, pathophysiology of, 124
Pulmonary conditions, cancer patients with, 272–273
Pulmonary disease
after cardiac surgery incidence, 291
prevention and treatment, 292
risk factors, 291–292
Pulmonary embolism (PE), 115, 126, 171, 263, 351, 463
bariatric surgery and, 357, 358, 364
clinical prediction rules for, 476
diagnosing, 474–476
management algorithm for, 477
post-delivery, 262
risk assessment of, clinical model for, 477t
Pulmonary evaluation
for bariatric surgery patient, 362, 364
physical examination, 118–119
post-bariatric surgery, 367
Pulmonary evaluation, preoperative, 44
history, 115–118
patient-related risk factors, 115–118
procedure-related risk factors, 118
Pulmonary function testing, 219, 359
Pulmonary medications, 53, 61
Pulmonary physiology, pregnancy and, 254
Pulmonary risk assessment/risk reduction, 115–127
approach to, 123
clinical prediction rules, 120–122
epidemiology, 115
history, 115–118
minimizing risk, 122–126
patient education, 127
physical examination, 118–119
postoperative management, 126
predicting risk/guidelines, 120
quality indicators, 126
testing, 119–120
Pulmonary risk factors, past medical history, 36
Pulmonary testing, pregnancy and, 256
QT interval prolongation, 415
Quality indicators
cancer patients and, 278
role of, 126
Quality of care
measuring, approaches to, 23–24
public reporting and improvement in, 21–22, 27–28
effects on outcomes, 28
effects on QI activity, 27
Quetiapine, 233, 448
Quinidine, 52
Q-waves, pathologic, preoperative ECGs for patients with, 42
RA. See Rheumatoid arthritis
Radiotherapy
cardiovascular conditions in cancer patients and, 269, 271
cardiovascular side effects of, 271t
Ramosetron, 428
Ramsey Sedation Scale, 329
RASS. See Richmond Agitation Sedation Scale
RBCs. See Red blood cells
RCRI. See Revised Cardiac Risk Index
Recombinant human activated protein C (rhAPC), for severe sepsis, 399–401
Red blood cells, major function of, 163
Referrals, 87
Referring providers, public reporting and impact on, 27
Reform. See Healthcare reform
Rehabilitation, for orthopedic surgery patient, 320
Reimbursement, perioperative medicine and, 89–90, 92
Reimbursement relationship, between RVUs and CPT codes, 86
Relafen, 223
Remeron Sol-Tab, route of administration and dose ranges, 234
Remifentanil, 156
Renal azotemia, prerenal azotemia vs., 194
Renal care, perioperative, conceptual model for, 512
Renal conditions
cancer patients with, 273–274
trauma patients and, 332–333
Renal disease
after cardiac surgery
incidence, 289–290
management of, 290–291
risk stratification, 290
age and, 187–188
anesthetic considerations, 191
cardiovascular evaluation, 189–191
electrolyte management and, 185–197
epidemiology, 185–186
perioperative management, 191–193
dialysis patients, 192–193
fluid management, 192
postoperative AKI, 193–197
electrolyte management, 195–197
major causes of, 194
prediction of risk
patient- and surgery-related, 186–187
risk indices, 188–189
Renal dysfunction, pain control for patients with, 522
Renal failure, 133, 194
Renal function, orthopedic surgery patient and, 319–320
Renal function tests, preoperative lab testing, recommendations for, 41
Renal insufficiency, postoperative, 193
Renal physiology, pregnancy and, 254
Renal replacement therapy, 185, 186, 188, 509
risk index for predicting, in cardiac surgery, 189
Renal transplantation, 190
Renal ultrasound, 194
Reporting. See Public reporting
RESOLVE trial, 401
Resource-based relative value (RBRV) system, 85
Respiratory failure, 115
Respiratory failure index, updated, 122
Reticulocyte count, 165, 166
Reticulocyte Production Index, 165, 165
Return on investment, 69
Revascularization, 99, 106
Revenue cycle setup, for preoperative clinics, 70
Review of systems (ROS), 37, 87–88
Revised Cardiac Risk Index, 36, 38, 42, 103, 105, 108, 115, 120, 188
Lee’s, 104
Rheumatoid arthritis, 215–217, 313
epidemiology, 215–216
history, 215–216
laboratory testing and imaging, 217
physical examination, 216–217
Rheumatologic conditions
management of, for surgery, 215–227
ankylosing spondylitis/psoriatic arthritis, 218–219
juvenile idiopathic arthritis, 217–218
rheumatoid arthritis, 215–217
perioperative medication management, 223–227
biologic agents, 226–227
corticosteroids, 224–225
leflunomide, 225–226
methotrexate, 225
nonbiologic disease-modifying agents, 226
NSAIDs, 223–224
systemic autoimmune diseases, 220–223
Richmond Agitation Sedation Scale, 329
Risk adjustment
limitations with, 30
problem with small sample and low event rates, 30–31
Risk reduction, 7
Risperdal, route of administration and dose ranges, 234
Risperidone, 57, 237, 238, 353, 444, 448
route of administration and dose ranges, 234
Rituxan, 226
Rituximab, 226–227, 226, 378, 379
Rivaroxaban, 468
Rivastigmine, 444
“Rivers protocol,” 394
ROI. See Return on investment
Ropivacaine, 526
Rosiglitazone, 133
Rosuvastatin, 109
Roux-en-Y gastric bypass (RYGB), 357, 358
diabetes management after, 367–368
discharge recommendations after, 369
mechanism for diabetes mellitus resolution after, 365
RPI. See Reticulocyte Production Index
RRT. See Renal replacement therapy

SAGES. See Society of American Gastrointestinal Endoscopic Surgeons
SAH, 348–349
SBPs. See Systolic blood pressures
SCD. See Sickle-cell disease
SCIP. See Surgical Care Improvement Project
SCIP protocols, 278
Scleroderma, 222
Scopolamine, transdermal, 429
Seizures
alcohol withdrawal and, 242
traumatic brain injury and, 328
Selection pathway, 21, 22
Selective serotonin reuptake inhibitors, 57, 233, 235, 353
Selegiline, 235
Selegiline patch, 235
Separate internal medicine and anesthesia clinics, 64
Sepsis, 385–403
in cardiothoracic surgery patients, 295
definitions of, 387–388, 387t
diagnosis biomarkers and diagnostic tests in, 388
epidemiology of, in surgical patients, 385–386
genetic variability in, 390–391
incidence and outcomes of, 385–386
pathophysiology of, 390, 390
protocol for early goal-directed therapy, 395
severe
definitions of, 387t
pathophysiology of, 390
rhAPC for, 399–401
septic shock vs., 402–403
staging, PIRO system for, 389t
Surviving Sepsis Campaign guidelines and sepsis bundles, 391–392, 392t
treatment strategies in, 391
variability in mortality rate of control arms of clinical trials, 386
Sepsis management bundle components (to be completed in 24 h)
insulin and glycemic control, 401–402
low-dose steroids, 397–399
recombinant human activated protein C, 399–401
Sepsis resuscitation bundle components (to be completed within 6 h)
antimicrobial therapy and source control, 392–394
fluid resuscitation, 394–396
hemodynamic support, 396–397
Sepsis-related organ failure assessment, 401
Septic pelvic thrombophlebitis, 263
Septic shock, 387, 387t
severe sepsis vs., 402–403
Serotonin, 427
Serotonin antagonists, PONV and, 427–430
Serotonin syndrome, 457, 457t
Serotonin-norepinephrine reuptake inhibitors, 57, 233, 235
Serum albumin, low, PPC risk and, 120
Serum aminotransferases, preoperative lab testing, recommendations for, 41t
Serum creatinine, 132, 507
AKI and increase in, 500
Service leadership, medical consult service and, 80
Setraline, route of administration and dose ranges, 234t
Sevoflurane, 155
SFAR. See French Society of Anesthesiology and Intensive Care Shock, 133
SIADH. See Syndrome of inappropriate antidiuretic hormone
Sickle-cell disease, 170–172
blood transfusion, 171
hydration, 171
hypothermia, 172
infection control, 172
oxygenation, 171
prevalence of, 170
Sickle-cell preparation, 166
Simponi, 226t
INDEX

Single-nucleotide polymorphisms, 391
Sinus node dysfunction, 414, 417
Sinusitis, 455, 457
SIRS. See Systemic inflammatory response syndrome
Sitagliptin, 133
SLE, 224
Sleep apnea, opioids and, 524
Sliding-scale insulin, 141
Small bowel obstruction (SBO), 304
Smoking cessation, 127, 279, 302
PPC rates and, 125–126
SMR. See Standardized mortality ratio
SNPs. See Single-nucleotide polymorphisms
SNRIs. See Serotonin-norepinephrine reuptake inhibitors
Social history, 37
Social phobia, 231
Society for Ambulatory Anesthesia, antiemetic guidelines, 429
Society for Thoracic Surgeons, 31
Society of American Gastrointestinal Endoscopic Surgeons, 258–259
Society of Critical Care Medicine, 387
Society of Hospital Medicine Glycemic Control Task Force, recommendations for insulin regimens, 141, 142t
Society of Thoracic Surgeons, National Cardiac Database, 285
Sodium fractional excretion of, 199
management, for neurosurgery patient, 342–345
SOFA. See Sepsis-related organ failure assessment
Soft tissue sarcomas, chemotherapies commonly used for, 315t
Soft tissue tumors, 309
Sorafenib, ischemia and, 271t
Sotalol, 52, 289
Spherocytes, 166
Spinal fusion, 309
Spine surgery, 340
Spirometry, 119, 120, 124
Spiavack Scoring System, 291
SPT. See Septic pelvic thrombophlebitis
SSIs. See Surgical site infections
SSRIs. See Selective serotonin reuptake inhibitors
SSS. See Spivack Scoring System
St. John’s wort, 236
pharmacologic effects and perioperative management recommendations for, 56t
Staffing
for medical consultation services, 78
at University of Miami preoperative clinic, 67
Stakeholders, identifying and defining expectations of, 14, 15
Standardized mortality ratio, for RA patients, 216
Staphylococcus aureus, 219, 455
surgical site infections, 487, 488t, 491, 495
Statins, 53, 409, 421, 509
perioperative, 108–109
stroke prevention and, 205–206
ST-Elevation MI (STEMI), 411, 413
Steroids exogenous, patient response to, 54
perioperative administration of, recommendations for, 55t
PONV prophylaxis, 430
stress dose, 224–225
Surviving Sepsis Campaign Guidelines for, 398, 399t
STOP questionnaire, 117
STOP-BANG questionnaire, for obstructive sleep apnea screening, 303t
Strabismus surgery, 379
Stress tests, 100–101, 111
Stroke, 36
cardiac surgery and, 286
carotid artery disease and, 292
perioperative, 201–207
age and, 202
incidence of, 201
management of patient at risk for, 204–207
proposed mechanisms for, 202–203, 203
reducing risk of, 205
risk assessment for, 203–204
theoretical mechanisms of, 202
postoperative atrial fibrillation and, 289
Structure, assessing quality of care and, 23
STS. See Society of Thoracic Surgeons
STS cardiac risk stratification scoring system, 287
ST-segment changes, postoperative EKG monitoring for, 109
Subarachnoid hemorrhage (SAH), 342, 348
Suboxone, 520
Substance abuse disorders, 240–243, 521
Substance P, 432
Subutex, 520
Success measures, for medical consultation service, 83–84, 83t
Succinylcholine, hyperkalemia in patients with CKD and, 191
Sulfasalazine, 226
Sulfonylureas, 53, 133
Sunitinib, cardiotoxicity and, 270t
Super consultant model, traditional consultant model vs., 82
Superficial incisional surgical site infections, 486t
Supraventricular arrhythmias, 413, 415–416, 418
Surgical Care Improvement Project, 25t, 26t
CARD2 quality metric, 110
Surgical expenditures, 85
Surgical history, 37
Surgical hospitals, most important current reporting initiatives on quality of, 25t
Surgical site, PPCs and, 118, 127
Surgical site infection, 485–496
classification and definitions related to, 485–487, 486t
epidemiology, 487–491
etiology, 487
risk factors, 487–491, 489t
transmission, 491
incidence of and costs tied to, 485 medical management, 495
orthopedic surgery and, 318
pathogenesis, 487
pathogens involved in, 488t
postoperative assessment, 494–495
postoperative fever and, 453–454
prevention strategies, 491–494, 492t
rates of, for selected surgical procedures based on basic risk index category, 490t
Surgical specialties, medical consultation program and, 80
Surviving Sepsis Campaign guidelines, 401, 403
for antibiotic therapy, 393t
for corticosteroids, 398, 399t
for glucose control, 403t
for glycemic control, 402
sepsis bundles, 391–392, 392t
for vasopressors, 396t
Swedish National Hospital Discharge Registry, 215
Syncope, 326
Syndrome of inappropriate antidiuretic hormone (SIADH), 343, 344
cerebral salt wasting vs., 345t
System integration, for preoperative clinics, 70
Systemic inflammatory response syndrome, definitions of, 387, 387t
Systemic lupus erythematosus (SLE), 220–221
epidemiology, 220
history, 220–221
laboratory testing, 221
Systolic blood pressures, 38
Tachyarrhythmias, 414
Tachycardias, medical management of, 414, 417–418
Taxanes, pulmotoxicity and, 272t
TBI. See Traumatic brain injury
TCAs. See Tricyclic antidepressants
TDD. See Total daily dose
Telehealth G-codes, 90
Temperature, normal human range for, 452
Temporomandibular involvement, in RA, 216–217
Ten Commandments of Effective Consultation, 4–5, 8t, 9, 81
Testing
anemia, 165–167
cardiac, 99
chronic kidney disease, 189–191
coronary artery disease, 100–101
diabetes and hyperglycemia, 132
to estimate PPC risk, 119–120
hepatobiliary system, 151
laboratory, 39–40
during pregnancy, 254–256
preoperative, 38–39
rheumatoid arthritis, 217
Thalassemia, 172
Theophylline, 507
Thiamine, for alcohol-dependent patients, 242, 243
Thiazolidinediones, 53, 133
Thienopyridine, 48, 49
Thionamides, 146
Thoracic trauma, 330
Thrombocytopenia, 163, 178–179
  cardiothoracic surgery and, 295
  causes of, 178
  defined, 178
  heparin-induced, 179
  trauma-induced, 336
  treatment of, 179
Thrombocytosis, 180
Thromboembolic complications, 115
Thromboembolic events, bridging therapy and concern for, 59
Thromboembolic risk, assessment of, 59
Thrombophilias, 180
Thromboprophylaxis
  mechanical, 465–468
  pharmacological, 468
  timing and duration of, 468–469
Thrombotic thrombocytopenic purpura (TTP), 166
Thyroid storm, 146
Thyroid disease
  ophthalmic surgery and, 379
  preoperative setting and, 144
TIBC. See Total iron-binding capacity
Ticlopidine, 49
Tinzaparin, 60
Tiotropium, 302
TIPSS. See Transjugular intrahepatic portosystemic shunt
Tocilizumab, 226r, 227
Toprol-XL, 108
Torsades de pointes, 239, 415, 417, 520
Total daily dose, of insulin, 140
Total hip arthroplasty (THA), 309
Total iron-binding capacity, 166
Total knee arthroplasty (TKA), 309
Toxic shock syndrome, 455, 457r
Trainees, medical consultation service and, 82–83
Tranexamic acid, 294
Transdermal scopolamine (TDS) patch, 429r, 430
Transesophageal dobutamine stress echo, 363r
Transferrin, 166
Transfusion of blood products, postoperative fever and, 457, 457t
Transient ischemic attack, 36, 292
Transjugular intrahepatic portosystemic shunt, 152, 152r, 153
Transparency initiatives, 32
  hospital selection and limited effects of, 26
  quality of care, patient outcomes and, 21–22
  reducing healthcare costs and, 28
  unintended consequences, 28–30
  adverse selection or “cherry picking,” 29
  causing patients to make poor choices, 29–30
  gaming, 29
  overuse, 28–29
  “teaching to the test,” 29
Trastuzumab, cardiotoxicity and, 270t
Trauma
  abdominal compartment syndrome, 334–335
  anemia, 333
  blunt cardiac injury, 330–331
  coagulopathy, 335–336
  delirium tremens, 331
  glycemic control and, 332
  kidney injury, 332–333
  medical disease presenting with, 325–326
  medical management of, 325–336
  nutrition, 334
  sedation and analgesia, 328–330
  thoracic, 330
  venous thromboembolism after, 331–332
Traumatic brain injury, 326–328, 340
Traumatic Coma Data Bank, 327
Treadmill exercise ECG, 363r
Tricyclic antidepressants, 57, 235–236
Trihexyphenidyl, 238
Triiodothyroxine, 146
Tropisetron, 428
TDM, resolution of, defined, 366
Tuberculosis, detecting, preoperative CXRs and, 43
Tumor necrosis factor-alpha inhibitors, 303, 378
Typical antipsychotics, 238

UHealth Preoperative Assessment Center
(University of Miami)
building team at, 65
business case development for, 68–69
business case outline, 69
project development for, 66–68
establishing need, 66
facility design and outfitting, 67–68
forecasting demand, 67
information systems, 68
process flow, 66–67
staffing, 67
work groups, 66

Understaffing, hospitalist programs and, 14
Unfractionated heparin
bridging therapy and, 59
pregnancy and, 262, 264

Unipolar depression, 233, 234–236
University of Miami
combined internal medicine and anesthesia clinic at, 64–65
UHealth Preoperative Assessment Center at, 65

Unnecessary tests, disadvantages of, 38
UPAC. See UHealth Preoperative Assessment Center

Urinary tract infection
peripartum fever and, 258, 263
postoperative fever and, 454, 457t
U.S. National Hospital Discharge Survey, 97

U.S. News & World Reports, surgical hospitals’ quality, 25t
U.S. Renal Data System, 185
UTI. See Urinary tract infection

VA Coronary Artery Surgery Study, 503
Valium, 232t
Valproic acid, 57, 236, 242
Valrubicin, cardiotoxicity and, 270t
Vancomycin, 318
Vancomycin-resistant enterococci (VRE), surgical site infections and, 491, 495
Vasopressin deficiency, septic shock and, 396–397
Vasopressors, Surviving Sepsis Campaign guidelines for, 396t
VASST TRial, 397
VAT. See Ventilatory anaerobic threshold
Valrafaxine, 235
Venous foot pump, 465
Venous thromboembolism, 59, 180
abdominal and pelvic surgeries and, 301, 304, 305, 306
ACCP prophylaxis recommendations, 2008, 469t–470t
ACCP recommendations for initial treatment and secondary prevention of, 479t
background/epidemiology, 463
cancer patients and, 272, 277, 278, 278 clinical presentation, 471
diagnosis of, 471, 473–474
inflammatory bowel disease and, 303
management of, 478–479, 480t
obesity and risk for, 364
pathophysiology, 464
postoperative, 7
fever and, 455, 457t, 459
postpartum, 264
pregnancy and, 258
prevention of, 464–471
quality indicators, 481
risk assessment, 465
risk factors for, 463, 464, 466t
special management considerations for, 480t
in trauma patients, 331–332
Venous thromboembolism prophylaxis, 351
neurosurgery patients and, 342
University of Washington guidelines, 352t
orthopedic patients and, 313, 316–317, 321
Ventilatory anaerobic threshold, 120
Ventricular arrhythmias, 413–414, 415
Ventricular tachycardia, nonsustained and sustained, 288
Verapamil, 52
Veterans Administration, 520
Vinblastine, ischemia and, 271t
Vinca alkaloids, pulmotoxicity and, 272t
Vincristine, ischemia and, 271t
Vinorelbine, ischemia and, 271t
Virchow’s triad, 331, 464
INDEX 569

VISEP study, 402
Vital signs, physical exam, 38
Vitamin B₁₂ anemia, 168
Vitamin D
deficiency, osteoporosis and, 319
supplementation, osteoporosis treatment
and, 321
Vitamin K, 302
Vitamin K antagonist, VTE prophylaxis in
HFS patients and, 316
Voltaren, 223
Vomiting. See also Postdischarge nausea
and vomiting; Postoperative nausea
and vomiting
mechanism of, 425–426, 426
von Willebrand disease (vWD), prevalence
of and variants with, 174–175
VTE. See Venous thromboembolism

Warfarin, 36
bridging therapy, 59
perioperative stroke and, 205
risk stratification for patients on, 58
Warm antibodies, AIHA and, 172, 173
Wells’ criteria, for DVT, 473, 474
Wells model, for pulmonary embolism, 476
Wernicke-Korsakoff encephalopathy, 240,
243
White blood cell count, preoperative lab
testing, recommendations for, 41
WHO. See World Health Organization
Wilson’s disease, 151, 157
Withdrawal seizures, 240
Wolff-Parkinson-White syndrome, 414
Work relative value units, 78
World Health Organization, 163
wRVUs. See Work relative value units

Xanax, 232

Ziprasidone, 57, 237, 239
route of administration and dose ranges, 234
Zofran, 428
Zoloft, route of administration and dose
ranges, 234
Zydis, 57
route of administration and dose ranges, 234
Zyprexa, route of administration and dose
ranges, 234